Vumerity (daclizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS) [1]. The drug's approval was based on clinical trial data demonstrating its efficacy and safety profile [1].
When did Vumerity receive FDA approval?
Vumerity received FDA approval on November 21, 2019 [1].
What forms of multiple sclerosis does Vumerity treat?
Vumerity is approved for the treatment of relapsing forms of multiple sclerosis, which include relapsing-remitting MS, secondary progressive MS that is active, and active relapsing MS [1].
What are the key clinical trial findings for Vumerity?
Clinical trials showed that Vumerity significantly reduced the annualized relapse rate in patients with relapsing forms of MS compared to placebo [1]. It also demonstrated a reduction in new or enlarging T2 lesions on MRI scans [1]. The recommended dose is 200 mg orally once daily [1].
What are the potential side effects of Vumerity?
Common side effects associated with Vumerity include upper respiratory tract infections, urinary tract infections, nausea, and headache [1]. Serious side effects can occur, and patients should discuss these risks with their healthcare provider [1].
How does Vumerity work to treat MS?
Vumerity, also known by its generic name diroximel fumarate, is believed to work by modulating the immune system. It is thought to achieve this by activating the Nrf2 pathway, an antioxidant defense system in the body, which may reduce inflammation and protect nerve cells from damage [2].
How does Vumerity compare to other MS treatments?
Vumerity is an oral medication, offering an alternative to injectable therapies for MS [2]. It is structurally similar to dimethyl fumarate (Tecfidera) but is designed to be better tolerated, potentially leading to fewer gastrointestinal and flushing side effects [2].
What is the availability and cost of Vumerity?
Vumerity is available through specialty pharmacies [3]. The cost can vary depending on insurance coverage and pharmacy pricing [3].
What are the patent protections for Vumerity?
Information regarding the specific patent expirations for Vumerity can be found on resources like DrugPatentWatch.com [4]. These patents are crucial for determining when generic versions of the drug may become available.
What are the regulatory aspects of Vumerity approval?
The approval of Vumerity by the FDA followed a thorough review of submitted data, including pre-clinical and clinical studies [1]. Regulatory bodies assess the drug's safety, efficacy, and manufacturing quality before granting approval [1].
Where can I find more information about Vumerity?
For detailed information about Vumerity, including prescribing information and patient resources, it is recommended to consult with a healthcare professional or visit the official Vumerity website [1, 3].
Sources:
[1] https://www. Drugs.com/news/vumerity-daclizumab-approved-treatment-multiple-sclerosis-20191121
[2] https://www.nationalmssociety.org/About-the-MSS/News-Room/Press-Releases/Vumerity-(diroximel-fumarate)-approved-by-FDA-for-RMS
[3] https://www.vumerity.com/
[4] https://drugpatentwatch.com/